Divis Lab recent developments

Divi's Lab is shedding its image as a standard generic API supplier and re-rating as an elite, high-tech global CDMO partner. The operationalization of Kakinada, the validation of peptide streams, and structural integration are the true fundamental pillars driving its premium valuation. The company continues to maintain industry-leading profitability, with its core EBITDA margins holding a resilient 33.0% range as of Q4 FY26. While short-term margins have faced minor pressure from raw material inflation and product-mix shifts, the company’s structural pivot toward Custom Synthesis (which now accounts for 56% of total revenue) is expected to act as a high-margin cushion moving forward. On the valuation front, the stock trades at a premium trailing P/E of roughly 69x–70x. While this reflects an expensive multiple relative to generic peers, the market is pricing in a massive, debt-free capital expenditure cycle (₹2,520 crore deployed in FY26 alone). Looking ahead, institutional consensus expects a sharp revenue and earnings acceleration starting late FY27 and heading into FY28. This future growth will be heavily driven by the commercial scale-up of the Kakinada greenfield hub, fast-tracked contrast media contracts, and initial revenue streams from their newly constructed peptide facilities, projecting a strong 18% to 19% EBITDA and PAT CAGR over the FY26–FY28 period.